Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a
single drug in HRD positive ovarian cancer patients for multi-line therapy. Bevacizumab is a
recombinant humanized monoclonal antibody that inhibits tumor angiogenesis and is also
recommended for the treatment of recurrent ovarian cancer. Clinical studies showed that
niraparib combined with bevacizumab could significantly prolong progression free survival of
platinum sensitive recurrent ovarian cancer. We intend to conduct a single-arm, prospective,
open-label, phase II study to observe the efficacy and safety of niraparib combined with
bevacizumab in the treatment of FIGO III/IV platinum refractory/resistant ovarian cancer,
fallopian tube cancer and primary peritoneal cancer. The results are expected to provide more
effective and precise treatment for platinum resistant recurrent/refractory ovarian cancer
patients.